Last updated on December 2019

AsiDNA (a DNA Repair Inhibitor) Administered IntraVenously in Advanced Solid Tumors

Brief description of study

The aim of the study is to assess:

  • Part A: the safety, pharmacokinetics, pharmacodynamics and preliminary efficacy of AsiDNA in patients with advanced solid tumors.
  • Part B: the safety and preliminary efficacy of AsiDNA in combination with Carboplatin with or without Paclitaxel in patients with Advanced solid tumors.

Clinical Study Identifier: NCT03579628

Find a site near you

Start Over

Grand H pital de Charleroi

Charleroi, Belgium
  Connect »